Cytokinetics rises after heart disease drug shows promise in late-stage study

Cytokinetics, Incorporated

28/08/2026 11:41

** Shares of drugmaker Cytokinetics CYTK.O rise 1.7% to $79.27 premarket
** CYTK says detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments
** The drug is already approved as Myqorzo for oHCM — the obstructive form of the condition called hypertrophic cardiomyopathy in which thickened heart muscles block ​blood flow
** Myqorzo competes with Bristol Myers Squibb's BMY.N Camzyos in the oHCM segment 
** The company is seeking to expand its use to the non-obstructive form (nHCM), which causes heart muscle thickening without blocking blood flow
** As of last close, CYTK stock was up 22.6% YTD 

(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))